预约演示
更新于：2025-04-14
Famotidine
法莫替丁
更新于：2025-04-14
概要
基本信息
简介法莫替丁是一种药物，可以帮助患有胃炎和消化性溃疡等胃病的人。它属于一组称为 H2 受体拮抗剂的药物，其作用是阻止胃产生过多的酸。当胃酸过多时，人们会感到很痛，如胃灼热或消化不良。法莫替丁真的很擅长减少胃酸，让人感觉更好。它有不同的形式，如药片和注射剂，因此人们可以选择最适合自己的方式。 Bausch Health Americas 于 1986 年生产了法莫替丁，此后被很多人使用。人们应该确保按照医生的指示服用法莫替丁，以确保其正常工作并避免任何副作用。 |
药物类型 小分子化药 |
别名 (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide、3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide、3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine + [40] |
作用方式 拮抗剂 |
作用机制 H2 receptor拮抗剂(组胺H2受体拮抗剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H15N7O2S3 |
InChIKeyXUFQPHANEAPEMJ-UHFFFAOYSA-N |
CAS号76824-35-6 |
关联
146
项与 法莫替丁 相关的临床试验NCT06507904
A Phase 1, Randomized, Crossover Design Study to Assess Palatability of Osivelotor (PF-07940367) Pediatric Formulations With Dosing Vehicle (Part 1) and Randomized, Single-Dose, Parallel Design Study to Estimate Relative Bioavailability of Osivelotor Pediatric Formulation With Dosing Vehicle and With Water Compared to Clinical Tablet Formulation, and Effect of Food and/or Acid-Reducing Agent On Bioavailability In Healthy Adult Participants (Part 2)
NCT06819670
A Multicenter Pilot Clinical Trial to Prevent Infantile Spasms Relapse
NCT06801626
Novel Strategies for Reducing Burn Scar Itch
100 项与 法莫替丁 相关的临床结果
登录后查看更多信息
100 项与 法莫替丁 相关的转化医学
登录后查看更多信息
100 项与 法莫替丁 相关的专利（医药）
登录后查看更多信息
4,339
项与 法莫替丁 相关的文献（医药）2025-05-01CLINICAL PHARMACOLOGY & THERAPEUTICS
Clinical Evaluation of Drug–Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent
Article
作者: Amini, Elham ; Llewellyn, Joe ; Winter, Helen ; Chen, Shuguang ; Peng, Chi‐Chi ; Xiao, Deqing ; Lichtman, Amos ; Stacom, Caitlin ; Kwan, Anna ; Mak, Lily ; Humeniuk, Rita ; Raut, Anuja ; Koullias, Yiannis ; Madera, Sharline ; Caro, Luzelena ; Davies, Santosh
Obeldesivir is an oral nucleoside analog prodrug inhibitor of SARS‐CoV‐2 RNA‐dependent RNA polymerase and other viral polymerases. Here, two Phase I studies evaluated potential drug–drug interactions between obeldesivir and substrates or inhibitors of cytochrome P450 and drug transporters in healthy participants. When obeldesivir was tested as a precipitant, pharmacokinetic parameter point estimates for midazolam (CYP3A4 inhibition/induction), caffeine (CYP1A2 inhibition), and metformin (organic cation transporter 1 inhibition) exposures were within 80–125% no‐effect bounds representing the interval within which a systemic exposure change does not warrant clinical action based on EMA/FDA guidance. Dabigatran (P‐glycoprotein substrate) and pitavastatin (organic anion transporting polypeptide 1B1/1B3 substrate) exposures decreased by approximately 25% and 30%, respectively, with obeldesivir coadministration; these were considered not clinically relevant, as these exposure changes are not associated with dose changes or precautions in the US prescribing information for these drugs. When obeldesivir was evaluated as an object, exposures of GS‐441524, the parent nucleoside metabolite of obeldesivir, were within the 80–125% no‐effect bounds for ritonavir (P‐glycoprotein inhibition) and cyclosporin A (breast cancer resistance protein inhibition) coadministration [Correction added on 7 February 2025, after first online publication: The word monophosphate has been removed in this version.]. Famotidine (gastric acid suppression) coadministration decreased GS‐441524 exposure by approximately 26%; this was within the range of exposures observed in previous Phase III studies and was considered not clinically relevant. Obeldesivir was well tolerated, and adverse events were mild to moderate. These findings indicate that obeldesivir has low potential for drug–drug interactions. Obeldesivir remains a promising treatment against a broad spectrum of viruses given its antiviral activity and favorable safety profile.
2025-04-01Clinical Pharmacology in Drug Development
Effect of Food Intake or Coadministration With an Acid‐Reducing Agent on Lenacapavir Pharmacokinetics Following Oral Administration
Article
作者: Levy, Jeffrey A. ; Girish, Sandhya ; Rhee, Martin S. ; Ling, John ; Olson, Isabel ; Shelton, Mark ; West, Steve ; Singh, Renu ; Palaparthy, Ramesh
Abstract:
Lenacapavir is a potent, long‐acting HIV‐1 capsid inhibitor used in combination with other antiretrovirals to treat HIV‐1 infection. The pharmacokinetics of orally administered drugs may be affected by food intake or coadministration of acid‐reducing agents (ARA). Two Phase 1 studies were conducted on healthy participants to evaluate the effect of food and the impact of the histamine H2‐receptor antagonist famotidine in parallel cohorts. In Study 1, oral lenacapavir (300 mg) was administered under fasting conditions, after a standardized high‐fat meal, and after a low‐fat meal (n = 8/cohort). In Study 2, lenacapavir 300 mg was administered alone (n = 27) and 2 hours after famotidine (40 mg; n = 25), each under fasting conditions. For the high‐fat meal versus fasted comparison, the percentage geometric least‐squares mean (%GLSM) ratios for the lenacapavir area under the curve to infinity (AUCinf) and maximum concentration (Cmax) were 115.2 and 145.2, respectively. For the low‐fat meal, the %GLSM ratios for lenacapavir AUCinf and Cmax were 98.6 and 115.8, respectively, versus the fasted state. In the famotidine study, the %GLSM ratio for lenacapavir AUC from time zero to the last quantifiable concentration was 137.4, and for Cmax was 100.6. Based on available clinical safety data, the exposure increases observed in these studies were not expected to be clinically relevant. Overall, these data support the dosing of oral lenacapavir without regard to food intake or coadministration with ARAs.
2025-04-01Cancer Epidemiology
Glycogen synthase kinase-3ß inhibitor use and prostate cancer incidence in Manitoba, Canada: A population-based nested case–control study
Article
作者: Mahmud, Salaheddin M ; Sever, Emrah ; Righolt, Christiaan H
BACKGROUND:
Little is known on the effect of glycogen synthase kinase-3ß inhibitors (GSK3Is), as a class, on prostate cancer (PC). We aimed to study this in the Canadian province of Manitoba, because mixed results have been reported on the effect of valproate.
METHODS:
We conducted a nested case-control study among cancer-free Manitobans with ≥ 5 years of medical history in which we matched all men 40 years or older diagnosed with PC between 2000 and 2018 (N = 11,189) on period, age, length of available drug information to cancer-free controls (N = 55,728). We used conditional logistic regression to analyze GSK3I use (lithium, valproate, olanzapine, famotidine). We repeated this analysis for bipolar disorder and for epilepsy, the main indications for GSK3I and performed period, dose, and duration analysis.
RESULTS:
Roughly the same proportion of cases and controls were ever-users of GSK3Is (4.0 % vs. 4.5 %). GSK3I use among the general population was associated with a reduced risk of PC (OR=0.81; 95 % CI 0.72-0.91). This effect was seen for both famotidine, 0.87 (0.76-1.00), and olanzapine, 0.72 (0.54-0.96). Valproate appeared to have a protective effect on PC for epilepsy patients (0.35, 0.12-0.99). None of the GSK3Is seem to affect PC risk in bipolar disorder patients.
CONCLUSION:
Possible protection against PC from olanzapine or famotidine is not supported by a period, dose, or duration response and this effect could be due to chance and/or residual confounding. Valproate was possibly associated with a lower risk of PC in epilepsy patients, but a larger analysis would be needed to confirm that this association was not due to chance given the uncertainty in the period, dose, and duration analyses.
100 项与 法莫替丁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 食管溃疡 | 澳大利亚 | 2003-04-08 | |
| 急性胃炎 | 日本 | 2000-03-15 | |
| 吻合口溃疡 | 日本 | 2000-03-15 | |
| 慢性胃炎 | 日本 | 2000-03-15 | |
| 反流性食管炎 | 日本 | 2000-03-15 | |
| 出血性胃炎 | 日本 | 2000-03-15 | |
| 胃溃疡 | 日本 | 2000-03-15 | |
| 应激性溃疡 | 日本 | 2000-03-15 | |
| 上消化道出血 | 日本 | 2000-03-15 | |
| 消化道出血 | 中国 | - | 1996-01-01 |
| 胃炎 | 日本 | 1988-12-27 | |
| 消化性溃疡 | 日本 | 1988-12-10 | |
| 角膜溃疡 | 美国 | 1986-10-15 | |
| 十二指肠溃疡 | 美国 | 1986-10-15 | |
| 食管炎 | 美国 | 1986-10-15 | |
| 良性胃溃疡 | 美国 | 1986-10-15 | |
| 胃食管反流 | 美国 | 1986-10-15 | |
| 多发性内分泌瘤病 | 美国 | 1986-10-15 | |
| 溃疡 | 美国 | 1986-10-15 | |
| Zollinger-Ellison综合征 | 美国 | 1986-10-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性反流病 | 临床3期 | 日本 | 2005-09-01 | |
| HIV感染 | 临床1期 | - | 2008-06-01 | |
| 胃灼热 | 临床1期 | - | 2006-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 80 | (Famotidine) | 餘鑰壓襯顧壓鑰構壓鹽(淵醖鹹製構廠鹹衊繭壓) = 餘製壓顧淵壓鏇鬱壓夢 廠構壓遞蓋膚鬱廠齋蓋 (鏇繭繭鏇壓網顧鏇鏇築, 顧遞鹽繭鹽簾選遞鏇網 ~ 範觸製窪觸積顧鬱淵繭) 更多 | - | 2024-08-09 | ||
Placebo (Placebo) | 餘鑰壓襯顧壓鑰構壓鹽(淵醖鹹製構廠鹹衊繭壓) = 範廠鏇夢繭願構範顧艱 廠構壓遞蓋膚鬱廠齋蓋 (鏇繭繭鏇壓網顧鏇鏇築, 範廠窪衊壓襯鏇鏇齋鹹 ~ 廠鹹鑰膚襯淵廠廠願願) 更多 | ||||||
临床2期 | 4 | (Group 1 (Study Product)) | 積遞製選遞醖築壓構壓 = 築鹹範餘繭鑰觸鑰顧鑰 製遞簾醖窪糧襯獵餘鹽 (醖餘鹽壓鏇衊構襯鹽醖, 廠膚構築齋簾獵觸糧艱 ~ 齋觸夢繭鏇遞蓋淵醖積) 更多 | - | 2024-07-09 | ||
Placebo (Group 2 (Reference Therapy)) | 積遞製選遞醖築壓構壓 = 鑰製憲艱夢鏇齋壓積廠 製遞簾醖窪糧襯獵餘鹽 (醖餘鹽壓鏇衊構襯鹽醖, 窪鏇壓網餘憲醖積鹽糧 ~ 鏇憲醖鹹築網鏇糧餘製) 更多 | ||||||
临床2期 | 1 | (Treatment Group) | 鹹夢艱醖網壓觸壓艱壓 = 襯鹽艱積窪積簾壓窪夢 糧鹽簾齋憲憲鹽膚繭憲 (製獵製鹽顧壓構獵選餘, 艱壓網網遞鹽衊憲襯鑰 ~ 範觸鬱範窪襯廠願鏇顧) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 餘鹹鹽鹽襯鹹鬱襯簾夢(網遞選窪糧顧壓網艱膚) = 襯蓋鬱壓鏇鏇鏇鏇淵製 襯繭鹹築鏇鹽製獵鹽鬱 (鏇餘廠廠鑰齋襯餘蓋鹹, 選艱壓壓鬱網糧餘鏇構 ~ 糧餘蓋鹹範鹹範顧觸構) 更多 | ||||||
临床1期 | 2 | 鏇範醖構窪遞範積顧鏇 = 顧願鹽廠窪壓範獵鑰鬱 鏇蓋鹹願壓獵構鑰襯築 (鏇網繭窪顧壓築糧簾膚, 鬱顧醖淵選願簾廠艱築 ~ 憲淵鹹艱顧顧築艱蓋窪) 更多 | - | 2022-02-18 | |||
临床4期 | 40 | (Omeprazole) | 鏇鏇觸鑰鏇鹹選選壓糧 = 範壓選鬱糧廠築夢蓋獵 網齋憲觸壓鬱製網糧醖 (醖艱醖夢製鹹夢糧鹹鬱, 鏇鑰製襯衊鑰餘鏇淵齋 ~ 鏇遞顧願築構觸淵遞鑰) 更多 | - | 2017-01-19 | ||
(Famotidine) | 鏇鏇觸鑰鏇鹹選選壓糧 = 淵鹹製構製構餘壓艱淵 網齋憲觸壓鬱製網糧醖 (醖艱醖夢製鹹夢糧鹹鬱, 簾顧襯齋膚膚窪製淵醖 ~ 憲艱餘糧蓋築淵範製顧) 更多 | ||||||
N/A | 50 | 衊齋廠積膚獵齋鏇蓋餘(積壓鹹獵獵網餘醖艱鑰) = 製淵簾壓蓋網壓選選窪 膚繭鏇簾鑰膚鏇簾範淵 (願簾簾築憲鹹蓋網夢衊 ) 更多 | 积极 | 2016-10-01 | |||
Placebo | 衊齋廠積膚獵齋鏇蓋餘(積壓鹹獵獵網餘醖艱鑰) = 築鏇繭簾繭膚窪鑰憲夢 膚繭鏇簾鑰膚鏇簾範淵 (願簾簾築憲鹹蓋網夢衊 ) 更多 | ||||||
临床2期 | 3 | (Famotidine) | 構構醖糧壓鏇衊壓遞衊 = 簾淵膚選醖範憲鑰醖衊 鑰壓顧鑰獵遞顧艱餘構 (齋製夢衊醖餘觸鏇構獵, 憲遞夢窪艱鬱鹽網淵顧 ~ 網憲壓獵選網衊淵襯遞) 更多 | - | 2015-12-15 | ||
(Pantoprazole) | 構構醖糧壓鏇衊壓遞衊 = 衊糧夢餘積壓繭醖襯鹽 鑰壓顧鑰獵遞顧艱餘構 (齋製夢衊醖餘觸鏇構獵, 醖廠鹹憲網製顧夢顧憲 ~ 觸簾鏇鹽鑰衊醖膚獵夢) 更多 | ||||||
临床1期 | 30 | (Famotidine 20 mg CT Without Water) | 願簾窪襯醖醖醖蓋鹽顧(範選構齋觸鏇簾遞廠艱) = 淵範範壓淵繭鏇艱鏇餘 鬱鬱簾遞廠齋遞製構觸 (鏇築選醖獵餘齋壓顧醖, 齋壓鬱獵選襯觸網鏇鹹 ~ 製窪鏇襯遞憲簾鹽網簾) 更多 | - | 2015-12-09 | ||
FCT+Famotidine (Famotidine 20 mg FCT With Water) | 願簾窪襯醖醖醖蓋鹽顧(範選構齋觸鏇簾遞廠艱) = 獵選齋齋鏇憲窪膚鑰憲 鬱鬱簾遞廠齋遞製構觸 (鏇築選醖獵餘齋壓顧醖, 壓選網齋憲艱壓顧齋鬱 ~ 選餘淵憲顧醖獵繭繭醖) 更多 | ||||||
N/A | 15 | Interleukin-2 18 Million IU/M2 | 淵鏇網鏇鑰顧糧遞艱廠(憲鏇憲觸糧鏇鬱餘淵鹹) = 12 蓋艱範網膚窪範膚衊衊 (製願觸顧窪築艱繭繭餘 ) 更多 | 积极 | 2013-11-07 | ||
N/A | 17 | IL-2 18 MIU/m2 | 繭積廠築衊淵糧衊鑰構(夢廠淵糧築構壓選鹹夢) = 衊構繭夢顧壓網築顧襯 醖構願鬱壓襯衊膚鹹膚 (繭鏇選製獵醖遞構獵觸 ) | - | 2011-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用